Type 1 Diabetes Mellitus Stakeholder Engagement Innovation Center to Advance Health Equity (U2C Clinical Trial Not Allowed)

The summary for the Type 1 Diabetes Mellitus Stakeholder Engagement Innovation Center to Advance Health Equity (U2C Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Type 1 Diabetes Mellitus Stakeholder Engagement Innovation Center to Advance Health Equity (U2C Clinical Trial Not Allowed): This U2C funding opportunity announcement (FOA) is a National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) initiative to establish a novel national Stakeholder Engagement Innovation Center for advancing equity in type 1 diabetes research (SEIC-T1D). A primary goal of the SEIC-T1D is to accelerate equitable engagement of diverse stakeholders in T1D research, particularly those from diverse communities that experience diabetes-related health disparities, as well as the healthcare and social systems that impact community members and patients health. The SEIC-T1D will provide highly specialized research resources to support investigators by fully embedding communities, people living with T1D, and other stakeholders into the full spectrum of research activities through expert consultations and education in principles and methods of community-engaged research. The SEIC-T1D will also establish a network consisting of diverse, multidisciplinary research investigators with expertise in T1D and community-engaged methods, community experts with lived experiences, and representatives of various health and other organizations deemed essential for addressing disparities and advancing health equity in T1D early detection and treatment.

Federal Grant Title:	Type 1 Diabetes Mellitus Stakeholder Engagement Innovation Center to Advance Health Equity (U2C Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Food and Nutrition Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DK-22-019
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.847
CFDA Descriptions:	Information not provided
Current Application Deadline:	November 17th, 2022
Original Application Deadline:	November 17th, 2022
Posted Date:	July 22nd, 2022
Creation Date:	July 22nd, 2022
Archive Date:	December 23rd, 2022
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	July 22nd, 2022

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-019.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) ...; • Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Compl...; • Cooperative Centers for Experimental Hematology (CCEHs) (U54- Clinical Trial Not Allowed); • Limited Competition for the Continuation of the Caring for OutPatiEnts after Acute Kidney ...; • Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury...; • Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes; • Molecular Therapy Core Centers; • Pilot and Feasibility Program in Human Islet Biology
More Grants from the National Institutes of Health: • Systems Biology of Infection and Inflammation in Chronic Diseases (U19 Clinical Trial Not ...; • NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed); • Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional); • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...; • The NIDDK Disorders of Gastrointestinal Interoception Consortium (DGIC) - Clinical Researc...